Kalaris Therapeutics
KLRS
71 hedge funds and large institutions have $33.9M invested in Kalaris Therapeutics in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 25 reducing their positions, and 19 closing their positions.
10,000% more call options, than puts
Call options by funds: $202K | Put options by funds: $2K
0.11% less ownership
Funds ownership: 1.88% → 1.77% (-0.11%)
7% less funds holding
Funds holding: 76 → 71 (-5)
7% less capital invested
Capital invested by funds: $36.4M → $33.9M (-$2.53M)
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
36% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$4.3M |
| 2 |
RC
RBF Capital
San Francisco,
California
|
+$345K |
| 3 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$309K |
| 4 |
Millennium Management
New York
|
+$271K |
| 5 |
Two Sigma Advisers
New York
|
+$258K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.11M |
| 2 |
ICM
Irenic Capital Management
New York
|
-$1.95M |
| 3 |
State Street
Boston,
Massachusetts
|
-$734K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$481K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$316K |
KLRS Hedge Fund Activity: Q2 2024 in Review
71 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q2 2024, worth a combined $33.9M — down 7% from $36.4M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KLRS and 14 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 16 added.
The largest buyer was Octagon Capital Advisors, adding an estimated $4.3M. The largest seller was BlackRock, cutting an estimated $2.11M.
- 71 institutional investors held Kalaris Therapeutics (KLRS) as of Q2 2024, down from 76 in Q1 2024.
- Funds reported $33.9M of Kalaris Therapeutics stock for Q2 2024, down 7% quarter-over-quarter.
- 14 funds opened new Kalaris Therapeutics positions in Q2 2024 and 19 closed out, a net change of -5 holders.
- The largest Kalaris Therapeutics buyer in Q2 2024 was Octagon Capital Advisors, an estimated $4.3M added.
- The largest Kalaris Therapeutics seller in Q2 2024 was BlackRock, an estimated $2.11M sold.
Based on aggregated 13F filings for Q2 2024.